Skip to main content

CIML NK cells for recurrent ovarian cancer

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

  • RegistryNCT06321484
  • PhasePhase 1
  • StatusRecruiting
  • ConditionPlatinum-resistant Ovarian Cancer
  • SponsorDana-Farber Cancer Institute
How Intraperitoneal Cytokine-Induced Memory L… worksNCT063214841 min

What the film says

Read the transcript

Ovarian cancer usually answers to platinum chemotherapy at first. When it stops answering, the remaining drugs buy months, and most disease sits inside the abdomen, where it seeds the lining and causes fluid to build.

The idea: put trained natural killer cells exactly there.

At Dana-Farber, a patient's own natural killer cells are collected, then exposed overnight to three immune signals, interleukins 12, 15, and 18, which leaves them in a memory-like state: more alert, longer-lived. After chemotherapy makes room, the cells are infused directly into the abdominal cavity, followed by low doses of interleukin-2 under the skin to keep them active.

An early safety study for recurrent, platinum-resistant high-grade ovarian cancer. Rebecca Porter leads it in Boston. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06321484

    Platinum-resistant recurrence; limited options; peritoneal spread; Autologous NK cells via leukapheresis; CIML = IL-12/15/18 pre-activation; Lymphodepleting chemotherapy days −6 to −2; intraperitoneal infusion day 0; SC low-dose IL-2 day 0 and every other day ×4 (+1 more lines)

The drug

What is being tested.

Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.

Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion

This is an open-label, single site, phase 1b study to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer. Participants will be enrolled to test the safety of intraperitoneal CIML NK cell therapy The U.S. Food and Drug Administration (FDA) has not approved CIML NK cell therapy as a treatment for recurrent, high grade ovarian cancer.

The study

How the trial runs.

The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Participants must have histologically or cytologically confirmed recurrent epithelial ovarian cancer. Eligible histologies include high grade serous, high grade endometrioid and clear cell ovarian carcinoma.
  • Participants must have measurable cancer defined by RECIST 1.1 criteria.
  • Patients must have received at least 1 lines of prior systemic therapy and be deemed platinum resistant/intolerant by their treating oncologist. Patients with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment. Prior receipt of immune checkpoint blockade is allowed if grade 3 or higher toxicities were not experienced.
  • Age ≥18 years and <85 years old.
  • ECOG performance status of 0 or 1.
  • Participants must meet the following organ and marrow function as defined below:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.